Event details

Covid19 Vaccines and the Global Good: The Relationship between Universities, Pharmaceutical Companies and Government

Tuesday, 19 January 2021

A joint event with SRHE , ICHEM University of Bath and University of West Indies Office of Global Affairs
 
 

Universities have been a major source of innovation in responding to the  COVID19 pandemic including the development of  COVID19 vaccines. In the absence of production and distribution capacity, universities have partnered with large pharmaceutical corporations. These partnerships have raised difficult tensions including conflicts in intellectual property rights, licensing and the profit versus the public interest motive. Certain countries and organisations have called for the World Trade Organization  to suspend intellectual property rights related to COVID-19 to ensure that  all communities and countries, and not only the wealthiest, will have access to the vaccines. The  pharmaceutical industry and many high-income countries oppose this move, stating that innovation will be stifled when it is needed most. 

 

This seminar analyses the tensions that arise between governments, universities and large corporations in the development, production and distribution of vaccines in the context of a global pandemic. It raises major questions on how universities can proactively manage intellectual property rights; and points to alternative ways to develop these relationships in ways that protect and benefit humanity into the future.  

 

Speakers : Professor Duncan Matthews,(Director, Queen Mary Intellectual Property Research Institute) and Dr Roya Ghafele (Director, OxFirst)  

Respondent : Professor Ammon Salter ( ICHEM and CREI, School of Management, University of Bath)

Chair: Professor Rajani Naidoo   (Director ICHEM and co-ordinator SRHE SW Network)

Moderator: Professor Jurgen Enders  (ICHEM and CGHE)

 

 

Co-Hosts Dr  Luz longsworth (Pro Vice-Chancellor, UWI Office of Global Affairs)  Helen Perkins (Director, SRHE) and Francois Smit Dr Lisa Lucas ( University of Bristol and Co-ordinator SRHE SW Network) 

 

 

Speaker Abstracts and Bios

 

Socialised Risk, Privatised Reward: The Story of the Oxford/AstraZeneca Vaccine and Alternative Models for Equitable Access

Duncan Matthews

Rapid Covid-19 vaccine development has been underpinned by unprecedented levels of cooperation between universities and biopharma companies, supported by public funding from governments and not-for-profit organisations such as the Coalition for Epidemic Preparedness Innovations (CEPI). The decision of Oxford University to grant an exclusive licence to AstraZeneca for the manufacture and distribution of the AZD1222 vaccine worldwide has proved controversial and raises unanswered questions about equitable access, pricing and transparency. As public scrutiny of Covid-19 vaccines comes ever more sharply into focus, greater attention is being paid to the implications of intellectual property ownership, licensing agreements and the generation of profits and rewards. This presentation examines how public money invested in university-generated vaccine development can balance the exploitation of intellectual property rights with proper public scrutiny and equitable access.

 

Professor Duncan Matthews is Director of the Queen Mary Intellectual Property Research Institute and Chair in Intellectual Property Law. Apart from various university positions, he was previously a researcher in the National Institute for Economic and Social Research think-tank and  an EU lobbyist. He has acted as an advisor to amongst others the Directorate General Trade of the European Commission; the ECAP II EC-ASEAN Intellectual Property Rights Co-operation Programme; the American Association for the Advancement of Science and the United Nations Development Programme Expert Advisory Group on Trade and Development. He is a member of the Chartered Institute of Patent Attorneys Education Committee and also worked with the Centre for the Management of Intellectual Property in Health Research and Development on an IP Handbook of Best Practices. He is co-founder of the European Intellectual Property Teachers’ Network (EIPTN).



Speaker Abstract  (Forthcoming)


Preserving the Public Interest in Public Private Partnerships for Health

Roya Ghafele

To bring potentially lifesaving technology to market, universities need to enter partnerships with corporations. Such partnerships are commonly known as public-private partnerships for health and allow a university to combine its academic know-how with the commercial capabilities of a pharmaceutical company. These partnerships need to be guided by the preservation of the public interest. A university has a responsibility to protect the public interest, particularly if its research is undertaken with public support. To assure the preservation of the public interest, it is important that patents are adequately addressed in technology transfer agreements. This implies that on the one hand contracts contain public interest clauses and on the other hand that the licensing rate is commensurate with the need to preserve the public interest. In that respect valuing IP from a public interest perspective can be an important toolkit. As the Covid 19 pandemic spreads globally, universities around the world are encouraged to adequately assure the preservation of the public interest when transferring potentially lifesaving technology. Such an approach permits both the university and the company to adjust their respective strategies from the outset. 

 


 

 

Dr  Roya Ghafele has been the Director of OxFirst, an award-winning law and economics consultancy, since 2011. In addition, she has held a Lectureship (Assistant Professor) in International Political Economy with Oxford University and was also a tenured Lecturer (Assistant Professor) in Law with Edinburgh University. Prior to that she had post-doctoral assignments at Harvard and U.C. Berkeley. From 2002-2007 she worked as an Economist with the World Intellectual Property Organization (WIPO) and the OECD. She started her career with McKinsey in corporate finance. Her Ph.D. was awarded the Theodor Koerner Research Prize by the President of the Republic of Austria. Dr. Ghafele was trained at Johns Hopkins University, School of Advanced International Studies, the Sorbonne and Vienna University. During the course of her studies she was fully funded by the Austrian Government because her academic merits were continuously of outstanding quality. She is native in German and fluent in English, French and Italian. Her specialties include IP valuation,  Damage Calculations, Competition Law & Economics, FRAND, Royalty Rate Determination, Economic Assessment of Legal Contexts.

 

Please book directly by going to https://www.eventbrite.co.uk/e/covid19-vaccines-and-the-global-good-universities-and-pharmaceutical-co-tickets-133821775533 

Network: South West Regional Network
Date(s): Tuesday, 19 January 2021
Times: 14h00 -15h30 GMT
Signup Deadline: Friday, 15 January 2021
Location: online event, link will be provided
Lunch Provided: No
Spaces Left: Places available
Prices: Members: Free, Guests: Free
To book this event, please see the event description.
Worldwise news
Call for special issue - Studierbarkeit and Academic Success
Submit by 25.06.21
Networked Learning Conference
10/11 June
Covid-19 & SRHE events/activities
Update (December 2020)
SRHE membership benefits:
Engagement with
the global higher education research community…